Prophylactic Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC CO2) Versus Standard Surgery in Colorectal Carcinoma at High Risk Peritoneal Carcinomatosis. Short and Long-term Outcomes. CHECK STUDY
This is a phase III randomized, multicenter study with two different arm: * experimental: prophylactic surgery plus HIPEC CO2 performed with mitomycin * comparator: standard surgery Adjuvant treatment after surgery is mandatory except for documented cases of non-eligibility. Patient will be randomized in a 1:1 ratio. Randomization will be done during surgery if the total resection of tumour will be reached and will use a stratification procedure based on center
• Patients with histologically documented colorectal adenocarcinoma eligible for R0,
‣ Presurgical or intraoperative stage T4a or T4b primary tumour (TNM 8 th)
⁃ Urgent presentation: perforation without purulent generalized peritonitis or fecal peritonitis
⁃ Peritumoral minimal peritoneal carcinomatosis: limited peritoneal disease in close proximity to the primary tumour, that may be removed en bloc
⁃ Ovarian metastases (Krukenberg tumor)
• Age ≥ 18 and ≤75 years
• Written informed consent